and initially Quiltman
Acurastems drug candidate AS-202. My quick thoughts.
Half life of 30 to 50 minutes. You will remember a recent MSC candidate I spoke about with a short half life.
Intra spinal administration.
Loss of PIKfyve in platelets causes a lysosomal disease leading to inflammation and thrombosis in mice. Min et al, 2014
There is more than TDP-43 in MND/ALS, it is one major subset of the condition that we have to control.
A very recent Macquarie University longitudinal data study on MND in mice found DNAJB5 could also be the dual major trouble maker in the body.
Guess which drug influences that pathway called TXNIP which influences DNAJB5 ?
Youtube " fightmnd science series seminar, September 2023". It's heavy duty science webinar but to myself it enlightened me of another attribute of MPL.
Good luck to Acurastem. I believe that MT has some knowledge of targeted cell therapy and was saying to all. $580 million !
Kpax
Ann: Additional Phase 1 data suggest MPL may inhibit MND, page-334
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.005(2.27%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 21.5¢ | $194.1K | 889.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4996 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 114999 | 4 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |